| Título : |
Comparative effectiveness of human hematin and heme arginate in themanagement of porphyria attacks: an observational study across three hospitals inColombia |
| Tipo de documento : |
documento electrónico |
| Autores : |
Andrés Felipe Valencia Quintero, Autor ; Natalia Andrea Rojas Henao, Autor ; Enyd Estefanía Rave Builes, Autor ; Nieto López, Emmanuel Salvador, Autor |
| Fecha de publicación : |
2025 |
| Títulos uniformes : |
Hospital Practice
|
| Idioma : |
Inglés (eng) |
| Palabras clave : |
Porphyria hematin heme arginate treatment outcome Drug effects |
| Resumen : |
Background: Porphyria is an orphan disease classified as a genetic disorder caused by a partial or high-grade deficiency of enzymes involved in the synthesis of heme, an essential component of hemoglobin.This deficiency results in the accumulation of porphyrins (ALAS1 and PBG), intermediates in the hememetabolic pathway. This accumulation triggers porphyria attacks. In Colombia the Heme Arginate andHuman Hematin are the therapeutics alternatives for the management of porphyria AttacksObjective: To evaluate the comparative effectiveness of heme arginate versus human hemin fortreating porphyria attacks in hospitalized patients across three institutions in Medellin, Colombia.Methods: An observational and analytical study was conducted to compare the outcomes of treatmentwith human hematin versus heme arginate in clinical episodes of patients diagnosed with porphyriabetween 2015–2021.Results: In episodes treated with heme arginate (ArgH), 75% achieved pain control or reduction, 41.6%showed a reduction in opioid dosage, and 88.8% achieved resolution of the Porphyria attack. Forepisodes treated with human hematin (HH), 85.3% achieved pain control or reduction, 53.6% showeda reduction in opioid dosage, and 90.2% achieved resolution of the attack. When evaluating theeffectiveness of both treatments, no statistically significant differences were observed across thethree predefined effectiveness outcomes of the study.Conclusions: This study provides a comparative evaluation of heme arginate (ArgH) and humanhematin (HH) in the management of Porphyria attacks, demonstrating that both treatments are similarlyeffective in achieving pain control, reducing opioid use, and resolving clinical attacks. |
| Mención de responsabilidad : |
Natalia A Rojas Henao, Andres Felipe Valencia, Emmanuel Salvador Nieto López |
| DOI (Digital Object Identifier) : |
10.1080/21548331.2025.2520743 |
| Derechos de uso : |
CC BY-NC-ND |
| En línea : |
https://www.tandfonline.com/doi/full/10.1080/21548331.2025.2520743#abstract |
| Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis |
Comparative effectiveness of human hematin and heme arginate in themanagement of porphyria attacks: an observational study across three hospitals inColombia [documento electrónico] / Andrés Felipe Valencia Quintero, Autor ; Natalia Andrea Rojas Henao, Autor ; Enyd Estefanía Rave Builes, Autor ; Nieto López, Emmanuel Salvador, Autor . - 2025. Obra : Hospital PracticeIdioma : Inglés ( eng)
| Palabras clave : |
Porphyria hematin heme arginate treatment outcome Drug effects |
| Resumen : |
Background: Porphyria is an orphan disease classified as a genetic disorder caused by a partial or high-grade deficiency of enzymes involved in the synthesis of heme, an essential component of hemoglobin.This deficiency results in the accumulation of porphyrins (ALAS1 and PBG), intermediates in the hememetabolic pathway. This accumulation triggers porphyria attacks. In Colombia the Heme Arginate andHuman Hematin are the therapeutics alternatives for the management of porphyria AttacksObjective: To evaluate the comparative effectiveness of heme arginate versus human hemin fortreating porphyria attacks in hospitalized patients across three institutions in Medellin, Colombia.Methods: An observational and analytical study was conducted to compare the outcomes of treatmentwith human hematin versus heme arginate in clinical episodes of patients diagnosed with porphyriabetween 2015–2021.Results: In episodes treated with heme arginate (ArgH), 75% achieved pain control or reduction, 41.6%showed a reduction in opioid dosage, and 88.8% achieved resolution of the Porphyria attack. Forepisodes treated with human hematin (HH), 85.3% achieved pain control or reduction, 53.6% showeda reduction in opioid dosage, and 90.2% achieved resolution of the attack. When evaluating theeffectiveness of both treatments, no statistically significant differences were observed across thethree predefined effectiveness outcomes of the study.Conclusions: This study provides a comparative evaluation of heme arginate (ArgH) and humanhematin (HH) in the management of Porphyria attacks, demonstrating that both treatments are similarlyeffective in achieving pain control, reducing opioid use, and resolving clinical attacks. |
| Mención de responsabilidad : |
Natalia A Rojas Henao, Andres Felipe Valencia, Emmanuel Salvador Nieto López |
| DOI (Digital Object Identifier) : |
10.1080/21548331.2025.2520743 |
| Derechos de uso : |
CC BY-NC-ND |
| En línea : |
https://www.tandfonline.com/doi/full/10.1080/21548331.2025.2520743#abstract |
| Enlace permanente : |
https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis |
|  |
Inicio
Clasificado(s) por (Año de edición descendente) Refinar búsquedaComparative effectiveness of human hematin and heme arginate in themanagement of porphyria attacks: an observational study across three hospitals inColombia / Andrés Felipe Valencia Quintero ; Natalia Andrea Rojas Henao ; Enyd Estefanía Rave Builes ; Nieto López, Emmanuel Salvador
